Status:
UNKNOWN
Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
Lead Sponsor:
University Hospital, Brest
Conditions:
Juvenile Idiopathic Arthritis
COVID 19
Eligibility:
All Genders
Up to 17 years
Brief Summary
The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, th...
Eligibility Criteria
Inclusion
- Juvenile Idiopathic Arthritis satisfying Edmonton criteria
- Ongoing DMARD therapy or AINS for 3 months
Exclusion
- Inhability to consent
Key Trial Info
Start Date :
May 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 25 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04407923
Start Date
May 25 2020
End Date
November 25 2020
Last Update
May 29 2020
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
CH de Belfort
Belfort, France, 90015
2
CHU de Bordeaux
Bordeaux, France, 33000
3
CHRU de Brest
Brest, France, 29609
4
AP-HP Hôpital Kremlin-Bicêtre
Le Kremlin-Bicêtre, France, 94275